Article Sidebar

pdf
Date Published: 24/06/2025
Abstract Views: 251
Views pdf: 117
DOI: https://doi.org/10.51298/vmj.v550i1.14138
Issue
Vol. 550 No. 1 (2025)
Section
Các bài báo
How to Cite
Bùi Thế, D. ., Nguyễn Trần Tuyết, T., Trương Phi, H., & Châu Ngọc, H. (2025). SURVEY ON FACTORS RELATED TO ADVERSE EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN DIABETIC PATIENTS AT UNIVERSITY MEDICAL CENTER HO CHI MINH CITY. Vietnam Medical Journal, 550(1). https://doi.org/10.51298/vmj.v550i1.14138

SURVEY ON FACTORS RELATED TO ADVERSE EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN DIABETIC PATIENTS AT UNIVERSITY MEDICAL CENTER HO CHI MINH CITY

Dũng Bùi Thế, Trinh Nguyễn Trần Tuyết, Hùng Trương Phi, Hoa Châu Ngọc

Main Article Content

Abstract

Objective: To determine the rate and related factors of post-percutaneous coronary intervention (PCI) complications in diabetic patients. Subject and method: A retrospective study was conducted on 329 diabetic patients undergoing PCI at the University Medical Center HCMC from November 2022 to April 2023. Complications include stent thrombosis, in-stent restenosis, and major bleeding. Clinical and laboratory data were collected and analyzed. Results: Among 329 patients, the post-PCI complication rate was 23.5%. Stent thrombosis accounted for 10.3%, in-stent restenosis 9.7%, and major bleeding 3.5%. Factors associated with a higher complication rate include HbA1c >7% (OR=2.12; 95% CI: 1.35-3.33), a history of myocardial infarction (OR=2.64; 95% CI: 1.56-4.48), and impaired renal function (eGFR <60 ml/min, OR=1.85; 95% CI: 1.11-3.07). Conclusion: Post-PCI complications are common in diabetic patients, particularly those with high HbA1c levels, a history of myocardial infarction, and impaired renal function. Optimizing the management of these risk factors is suggested

Article Details

Keywords

diabetes mellitus, cardiovascular events, percutaneous coronary intervention, stent thrombosis, in-stent restenosis, bleeding risk

References

1. Mauri L and DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014. 371(23). p.2155-2166.
2. Konigstein M, et al. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention with Contemporary Drug-Eluting Stents. JACC Cardiovasc Interv. 2018. 11(24).p. 2467-2475.
3. Valgimigli M and MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021. 385(18). p. 1643-1655.
4. Kei-Yan Ng, et al. Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients. JACC Asia. 2022. 2(3). p. 341-349.
5. Jin HK, et al. Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus. Cardiovascular Interventions. 2017. 10(e004157).
6. European Society of Cardiology. Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021. 42(34). p.3227–3337.
7. Karadeniz F, et al. Impact of Admission, Fasting Glucose and HbA1c Levels on in-stent Restenosis in The Patients Treated with Primary Percutaneous Coronary Intervention in 5-Year Follow-up. Med Bull Haseki. 2021. 59(1):85-90.